As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...
A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified ...
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
Several recent studies have suggested HRT is a risk factor in various conditions, notably Alzheimer's - now UK boffins have ...
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
Summary: A new study has identified a biomarker, DTI-ALPS, which connects glymphatic system dysfunction to vascular dementia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback